SOPHiA GENETICS was founded in 2011 by biologists who had a vision to create a technology that could make a positive and lasting impact on the world, using data for good. We’ve built a revolutionary technology platform, SOPHiA DDM™, that rapidly distills complex data into actionable insights, enabling clinicians, researchers, and biopharma to reshape the way that we diagnose and treat cancer and rare inherited disorders. The AI fueling our platform learns from the complex genomic and multimodal data provided by our community of users to create a collective intelligence over time. By using the power of data and AI, we are expanding access to data-driven medicine and enabling the patients of today to help the patients of tomorrow. Our science is driven by unrelenting passion for our mission to transform patient care by expanding access to data-driven medicine globally. We wouldn’t be able to achieve all that we have – and all that we will – without our people, who are driven by our shared purpose to ensure that every patient worldwide has equitable access to precision medicine. Our virtues are our behaviors we exhibit every day, and our mantra “We Care” is our driving force.
解锁市场时间线与信号动态
最近 90 天内有 2,182 个信号。
该公司进入各个市场的顺序 — 从最早到最新
Como o Hospital Mário Penna incorporou NGS à rotina para diagnóstico de neoplasias hematológicas?Implementar uma nova tecnologia em laboratório clínico vai muito além da parte técnica — envolve confiança, adaptação e aprendizado contínuo.Neste webinar, a equipe do Hospital Mário Penna abre as portas do seu laboratório para contar como incorporou duas aplicações de NGS à rotina para investigação de neoplasias mieloides e linfoídes, desde a avaliação do desempenho analítico até os primeiros casos ...
A experiência do Hospital Mário Penna na implementação de soluções para investigação de doenças onco-hematológicas
注册以查看完整信号动态
SOPHiA GENETICS 的国际扩张与竞争对手的对比情况
SOPHiA GENETICS你条形图显示所对比公司之间的相对规模。
5 项指标| 公司 | 市场 | 新市场 | 势头 | 活动 | 扩张评分 |
|---|---|---|---|---|---|
 SOPHiA GENETICS你 | 11 | 0 | -54% | 2.2k | 21 |
快速扩张——最近 90 天新增 46 个职位，较上一周期增长 183%。 以 Sales 为主，集中在 瑞士。
Boston, MA · 前天
Senior Software Engineer
Singapore · 5天前
Director, Subject Matter Expert - APAC
Colombia · 上周
Associate Director / Sr Manager, BioPharma Business Development (West / Central)
在技术栈中检测到 50 项技术。
覆盖 226 个市场 的 32 个进行中的广告系列。
已结束
已结束
已结束最近 90 天获 3 次提及。
SOPHiA GENETICS SA发布了与2026年第二季度业绩电话会议相关的幻灯片,Seeking Alpha提供文字记录报道。
SOPHiA Genetics公布2026年第二季业绩,收入2,330万美元,同比增长27.2%,超出预期。GAAP每股亏损0.30美元,逊于预期0.08美元。毛利率降至64.6%(报告基准)和72.1%(调整基准)。
SOPHiA GENETICS宣布与阿斯利康展开多年合作,开发和部署两项精准肿瘤治疗的伴随诊断,在全球推进分散式临床试验检测。
解锁已验证邮箱与直拨电话
免费 · 无需信用卡
关于 SOPHiA GENETICS 的业务、市场和增长信号的快速解答。
